KR20250013180A - 아트라센탄에 의한 국소 분절 사구체경화증의 치료 방법 - Google Patents

아트라센탄에 의한 국소 분절 사구체경화증의 치료 방법 Download PDF

Info

Publication number
KR20250013180A
KR20250013180A KR1020247041241A KR20247041241A KR20250013180A KR 20250013180 A KR20250013180 A KR 20250013180A KR 1020247041241 A KR1020247041241 A KR 1020247041241A KR 20247041241 A KR20247041241 A KR 20247041241A KR 20250013180 A KR20250013180 A KR 20250013180A
Authority
KR
South Korea
Prior art keywords
subject
atrasentan
weeks
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247041241A
Other languages
English (en)
Korean (ko)
Inventor
앤드류 제임스 킹
빈센트 와이 입 통
마리안 카마르고
Original Assignee
치누크 세라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 치누크 세라퓨틱스, 인크. filed Critical 치누크 세라퓨틱스, 인크.
Publication of KR20250013180A publication Critical patent/KR20250013180A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247041241A 2022-05-19 2023-05-18 아트라센탄에 의한 국소 분절 사구체경화증의 치료 방법 Pending KR20250013180A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263343574P 2022-05-19 2022-05-19
US63/343,574 2022-05-19
PCT/US2023/022681 WO2023225163A1 (en) 2022-05-19 2023-05-18 Methods of treating focal segmental glomerulosclerosis with atrasentan

Publications (1)

Publication Number Publication Date
KR20250013180A true KR20250013180A (ko) 2025-01-31

Family

ID=88836135

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247041241A Pending KR20250013180A (ko) 2022-05-19 2023-05-18 아트라센탄에 의한 국소 분절 사구체경화증의 치료 방법

Country Status (10)

Country Link
US (1) US20250352511A1 (enExample)
EP (1) EP4525857A4 (enExample)
JP (1) JP2025517355A (enExample)
KR (1) KR20250013180A (enExample)
CN (1) CN119325377A (enExample)
AU (1) AU2023271840A1 (enExample)
CA (1) CA3252232A1 (enExample)
IL (1) IL316349A (enExample)
MX (1) MX2024013985A (enExample)
WO (1) WO2023225163A1 (enExample)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255931B2 (en) * 2010-06-24 2016-02-09 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
US20170014386A1 (en) * 2015-07-16 2017-01-19 Abbvie, Inc. Treatment of Multidrug-Resistant Nephrotic Syndrome (MDR-NS) in Children
CA3010593C (en) * 2016-01-05 2024-02-13 University Of Leicester Methods for inhibiting fibrosis in a subject in need thereof
IL294410B2 (en) * 2016-11-23 2024-02-01 Chemocentryx Inc A method for the treatment of focal segmental tuberous sclerosis
HRP20260121T1 (hr) * 2019-12-17 2026-03-13 Chinook Therapeutics, Inc. Farmaceutski prihvatljiva sol atrasentana za uporabu u postupku za liječenje iga nefropatije

Also Published As

Publication number Publication date
JP2025517355A (ja) 2025-06-05
EP4525857A1 (en) 2025-03-26
AU2023271840A1 (en) 2024-10-31
EP4525857A4 (en) 2026-05-20
IL316349A (en) 2024-12-01
MX2024013985A (es) 2025-02-10
US20250352511A1 (en) 2025-11-20
CA3252232A1 (en) 2023-11-23
CN119325377A (zh) 2025-01-17
WO2023225163A1 (en) 2023-11-23

Similar Documents

Publication Publication Date Title
JP7821870B2 (ja) アトラセンタンによるｉｇａ腎症を治療する方法
US20230270718A1 (en) Methods of treating diabetic kidney disease
US20250352511A1 (en) Methods of treating focal segmental glomerulosclerosis with atrasentan
US20220304979A1 (en) Methods of reducing disease flares
ES3062063T3 (en) A pharmaceutically acceptable salt of atrasentan for use in a method of treating iga nephropathy
HK40059453A (en) Methods of treating iga nephropathy with atrasentan
HK40094573A (en) Methods of treating iga nephropathy with atrasentan
BR122023026537A2 (pt) Uso de atrasentan para tratar nefropatia por iga

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000